MedPath

Vaginally Administered Versus Per Oral Misoprostol in Induction of Labour

Phase 4
Completed
Conditions
Labour Induction
Interventions
Drug: Misoprostol, modified-release pessary
Drug: Misoprostol, per-oral tablets
Registration Number
NCT02539199
Lead Sponsor
Tampere University Hospital
Brief Summary

The purpose of this study is to investigate the effectiveness and safety of vaginally administered misoprostol (Misodel) versus per orally administered misoprostol (Cytotec) in induction of labour in nulliparous women.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
270
Inclusion Criteria
  • Nulliparous
  • Singleton at term pregnancy (>36+6 weeks)
  • Unfavourable cervix (Bishop score < 6)
  • Fetal cephalic position
Exclusion Criteria
  • Pre-term pregnancy (<37 weeks)
  • Multiple pregnancy
  • Rupture of membranes
  • Other than fetal cephalic position
  • Intra-uterine growth retardation
  • Severe pre-eclampsia
  • Severe hypertension
  • Previous cesarean section

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Misoprostol modified-release pessaryMisoprostol, modified-release pessary-
Misoprostol, per-oral tabletsMisoprostol, per-oral tablets-
Primary Outcome Measures
NameTimeMethod
Cesarean section rateat time of child birth
Secondary Outcome Measures
NameTimeMethod
The time from beginning of induction to child birthup to child birth
Neonatal Apgar score1, 5, 10 minutes after child birth

Trial Locations

Locations (5)

Helsinki University hospital

🇫🇮

Helsinki, Finland

Turku University Hospital

🇫🇮

Turku, Finland

Kuopio University Hospital

🇫🇮

Kuopio, Finland

Oulu University Hospital

🇫🇮

Oulu, Finland

Tampere University Hospital

🇫🇮

Tampere, Finland

© Copyright 2025. All Rights Reserved by MedPath